Mechanism-resolving development of solid-tumor CAR T-cell therapy: linking programmable control to tissue pharmacodynamics
5 affiliations
- 1Institute of Research and Development, Duy Tan University
- 2Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital
- 3Vaxcell-Bio Therapeutics
- 4Department of Hematology-Oncology, Chonnam National University Hwasun Hospital and Chonnam National University Medical School
- 5Institute of Immunology and Human Genomics of the Academy of Sciences
Abstract
Solid-tumor CAR T-cell programs increasingly combine biomarker selection, lymphodepletion, manufacturing-state optimization, regional or repeated administration, and engineered control modules. This growing complexity creates a distinct translational problem: the same response, non-response, or toxicity can remain compatible with several competing explanations, obscuring which component actually operated in patient tissue. Mechanism-resolving development addresses this problem by treating each consequential engineering claim as a prospectively testable proposition embedded within the product-trial system. Four questions must be resolved: which patient-relevant state was present, which control action altered it, which proximal tissue transition followed, and which unsafe or limiting state emerged next. Each claim should therefore be paired with a clinically credible lower-burden counterfactual, mechanism-proximal tissue pharmacodynamics, a prespecified falsification criterion, a rescue strategy, and an adaptive action. Boolean coincidence and veto circuits, temporal IF-THEN systems, quantitative antigen-density filters, and genotype-conditioned activator-blocker designs require distinct representations, transition-state assays, and tissue biomarkers. Clinical evidence from CLDN18.2-directed satri-cel, compartmental central nervous system programs, hypoxia-responsive CEA therapy, GPC3-armored products, PSMA programs, and early HLA-loss-gated Tmod therapy illustrates that clinical maturity and mechanistic attribution are not equivalent. Programmability becomes translationally meaningful when the operation of an added control can be distinguished from credible alternatives in patient-relevant tissue, enabling complex cellular engineering to generate falsifiable, cumulative, and clinically actionable knowledge.
Related
- Cardiometabolic therapy for rhythm control: a case report of refractory atrial fibrillation resolving after initiation of semaglutide for obesity
- Beyond monocular acuity: Resolving the amblyopia treatment paradox with mechanism-targeted outcomes and modern testing methods
- Efficacy and safety of spleen-strengthening and phlegm-resolving herbal therapy for residual dizziness after repositioning of benign paroxysmal positional vertigo: a systematic review and meta-analysis of randomized controlled trials
- From Rescue Therapy to Mechanism-Based Sequencing in Refractory Myasthenia Gravis: A Narrative Review with an Illustrative Clinical Case
- Antibody Targeting Soluble NKG2D Ligand MIC Enhances Adoptive T-Cell Therapy in an NK Cell-Dependent Mechanism
BibTeX
@article{vo2026mechanismresolving,
title = {{Mechanism-resolving development of solid-tumor CAR T-cell therapy: linking programmable control to tissue pharmacodynamics}},
author = {Manh-Cuong Vo and Sang Ki Kim and Woo Kyun Bae and Nodirjon Ruzimurodov and Sung-Hoon Jung and Je-Jung Lee},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1983828},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1983828/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Mechanism-resolving development of solid-tumor CAR T-cell therapy: linking programmable control to tissue pharmacodynamics
AU - Manh-Cuong Vo
AU - Sang Ki Kim
AU - Woo Kyun Bae
AU - Nodirjon Ruzimurodov
AU - Sung-Hoon Jung
AU - Je-Jung Lee
PY - 2026
DA - 2026/10/22
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1983828
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1983828/full
AB - Solid-tumor CAR T-cell programs increasingly combine biomarker selection, lymphodepletion, manufacturing-state optimization, regional or repeated administration, and engineered control modules. This growing complexity creates a distinct translational problem: the same response, non-response, or toxicity can remain compatible with several competing explanations, obscuring which component actually operated in patient tissue. Mechanism-resolving development addresses this problem by treating each consequential engineering claim as a prospectively testable proposition embedded within the product-trial system. Four questions must be resolved: which patient-relevant state was present, which control action altered it, which proximal tissue transition followed, and which unsafe or limiting state emerged next. Each claim should therefore be paired with a clinically credible lower-burden counterfactual, mechanism-proximal tissue pharmacodynamics, a prespecified falsification criterion, a rescue strategy, and an adaptive action. Boolean coincidence and veto circuits, temporal IF-THEN systems, quantitative antigen-density filters, and genotype-conditioned activator-blocker designs require distinct representations, transition-state assays, and tissue biomarkers. Clinical evidence from CLDN18.2-directed satri-cel, compartmental central nervous system programs, hypoxia-responsive CEA therapy, GPC3-armored products, PSMA programs, and early HLA-loss-gated Tmod therapy illustrates that clinical maturity and mechanistic attribution are not equivalent. Programmability becomes translationally meaningful when the operation of an added control can be distinguished from credible alternatives in patient-relevant tissue, enabling complex cellular engineering to generate falsifiable, cumulative, and clinically actionable knowledge.
SN - 1664-3224
ER -